Apixaban-PK Trial: Preventing Portal Hypertension Complications in Cirrhosis

Recruiting Phase 4 Interventional Study
Cirrhosis Esophageal and Gastric Varices Ascites Hepatic Encephalopathy Portal Vein Thrombosis Portal Hypertension
Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Trial phase
Phase 4
Study type
Interventional
Purpose
Prevention
Participants needed
220 (estimated)
Sponsor
Asian Institute Of Medical Sciences · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
The APIXABAN-PK trial is a prospective, randomized, single-blind, placebo-controlled study designed to evaluate the efficacy and safety of apixaban in combination with carvedilol versus placebo with carvedilol in preventing portal hypertension-related complications in patients with cirrhosis. Conducted at the Gastroenterology and Hepatology Department and Clinical Trials Unit (CTU) of Asian Instit…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. Adults aged ≥18 years with diagnosed cirrhosis (any etiology), confirmed by histology, transient elastography (≥12.5 kPa), or consistent clinical/imaging findings. 2. Evidence of portal hypertension, defined by: Clinical: presence of varices on endoscopy, ascites, or sple…
Contacts

Fatima Nadeem Dr, Pharm-D, Mphil

+923080744996

fatima.nadeem2401@gmail.com

CONTACT